# Boehringer Ingelheim

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/boehringer-ingelheim/

## Facts

| Field | Value |
| --- | --- |
| Country | US |
| OpenAlex ID | https://openalex.org/F4320306257 |
| ROR ID | https://ror.org/05kffp613 |
| Works | 4,779 |

## Funder papers

- [Empagliflozin after Acute Myocardial Infarction](https://scholariq.org/papers/empagliflozin-after-acute-myocardial-infarction/)
- [Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists](https://scholariq.org/papers/dapagliflozin-in-hfref-patients-treated-with-mineralocorticoid-receptor/)
- [Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease](https://scholariq.org/papers/efficacy-and-safety-of-spironolactone-in-patients-with-hfpef-and-chronic-kidney/)
- [Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories](https://scholariq.org/papers/empagliflozin-and-cardiovascular-and-kidney-outcomes-across-kdigo-risk/)
- [Secondary analysis of the EMPACT-MI trial reveals cardiovascular–kidney efficacy and safety of empagliflozin after acute myocardial infarction](https://scholariq.org/papers/secondary-analysis-of-the-empact-mi-trial-reveals-cardiovascular-kidney-efficacy/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.